{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:49:33Z","timestamp":1769744973632,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["BR 5807\/1-1"],"award-info":[{"award-number":["BR 5807\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["BR 5807\/1-1"],"award-info":[{"award-number":["BR 5807\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["BR 5807\/1-1"],"award-info":[{"award-number":["BR 5807\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Antistaphylococcal penicillins and cefazolin have been used as first line therapy in Methicillin-susceptible Staphylococcus aureus bloodstream infection. While efficacy of both regimens seems to be similar, the compounds may differ with regard to tolerability. This study aims to describe the clinical use of cefazolin and flucloxacillin, focussing on discontinuation or change of anti-infective agent due to adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This observational prospective study was conducted at two German tertiary care centres with an internal recommendation of flucloxacillin for MSSA-BSI in one, and of cefazolin in the other centre. Adverse events were registered weekly under treatment and at a 90-day follow-up. Descriptive analysis was complemented by a propensity score analysis comparing adverse events (stratified rank-based test applied to the sum of Common Terminology Criteria for adverse events ratings per patient).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 71 patients included, therapy was initiated with flucloxacillin in 56 (79%), and with cefazolin in 15 (21%). The propensity score analysis indicates a statistically significant difference concerning the severity of adverse events between the treatment groups in favour of cefazolin (<jats:italic>p<\/jats:italic>\u2009=\u20090.019). Adverse events led to discontinuation of flucloxacillin in 7 individuals (13% of all patients receiving flucloxacillin). Clinical outcome was not different among treatment groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Using cefazolin rather than flucloxacillin as a first line agent for treatment of MSSA-BSI is supported by these clinical data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-023-02168-8","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T19:03:23Z","timestamp":1706727803000},"page":"1159-1163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Flucloxacillin and cefazolin for treatment of Staphylococcus aureus bloodstream infection"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-9565","authenticated-orcid":false,"given":"Kirsten","family":"Schmidt-Hellerau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Breuninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3246-5219","authenticated-orcid":false,"given":"Johanna","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0446-3224","authenticated-orcid":false,"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jomana","family":"Reusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-0772","authenticated-orcid":false,"given":"Norma","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5174-928X","authenticated-orcid":false,"given":"Martin","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-1871","authenticated-orcid":false,"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2168_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.eimc.2015.03.014","volume":"33","author":"F Gudiol","year":"2015","unstructured":"Gudiol F, Aguado JM, Almirante B, Bouza E, Cercenado E, Dom\u00ednguez M, et al. Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2015;33:626\u201332.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2168_CR2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132:1435\u201386.","journal-title":"Circulation"},{"key":"2168_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"LA Mermel","year":"2009","unstructured":"Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O\u2019Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1\u201345.","journal-title":"Clin Infect Dis"},{"key":"2168_CR4","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/jac\/dkz226","volume":"74","author":"JR Lenhard","year":"2019","unstructured":"Lenhard JR, Bulman ZP. Inoculum effect of \u03b2-lactam antibiotics. J Antimicrob Chemother. 2019;74:2825\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"2168_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2022.09.021","volume":"53","author":"A Bourreau","year":"2023","unstructured":"Bourreau A, Le Mabecque V, Broquet A, Caillon J. Prevalence of a cefazolin inoculum effect associated with blaZ gene types, and clinical outcomes among methicillin-susceptible Staphylococcus aureus blood isolates of patients with infective endocarditis. Infect Dis Now. 2023;53: 104626.","journal-title":"Infect Dis Now"},{"key":"2168_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/phar.2750","volume":"43","author":"K Antosz","year":"2023","unstructured":"Antosz K, Battle S, Chang J, Scheetz MH, Al-Hasan M, Bookstaver PB. Cefazolin in the treatment of central nervous system infections: a narrative review and recommendation. Pharmacotherapy. 2023;43:85\u201395.","journal-title":"Pharmacotherapy"},{"key":"2168_CR7","doi-asserted-by":"publisher","first-page":"0fab476","DOI":"10.1093\/ofid\/ofab476","volume":"8","author":"EE Pliakos","year":"2021","unstructured":"Pliakos EE, Ziakas PD, Mylonakis E. The cost-effectiveness of cefazolin compared with Antistaphylococcal Penicillins for the treatment of methicillin-sensitive Staphylococcus aureus bacteremia. Open Forum Infect Dis. 2021;8:0fab476.","journal-title":"Open Forum Infect Dis"},{"key":"2168_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","volume":"25","author":"S Weis","year":"2019","unstructured":"Weis S, Kesselmeier M, Davis JS, Morris AM, Lee S, Scherag A, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2019;25:818\u201327.","journal-title":"Clin Microbiol Infect"},{"key":"2168_CR9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/bcp.13554","volume":"84","author":"JP Rindone","year":"2018","unstructured":"Rindone JP, Mellen CK. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia. Br J Clin Pharmacol. 2018;84:1258\u201366.","journal-title":"Br J Clin Pharmacol"},{"key":"2168_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/MCC.0000000000000974","volume":"28","author":"A Tabah","year":"2022","unstructured":"Tabah A, Laupland KB. Update on Staphylococcus aureus bacteraemia. Curr Opin Crit Care. 2022;28:495\u2013504.","journal-title":"Curr Opin Crit Care"},{"key":"2168_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","volume":"18","author":"C Shi","year":"2018","unstructured":"Shi C, Xiao Y, Zhang Q, Li Q, Wang F, Wu J, et al. Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis. BMC Infect Dis. 2018;18:508.","journal-title":"BMC Infect Dis"},{"key":"2168_CR12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cmi.2020.08.044","volume":"27","author":"R Lecomte","year":"2021","unstructured":"Lecomte R, Bourreau A, Deschanvres C, Issa N, Le Turnier P, Gaborit B, et al. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. Clin Microbiol Infect. 2021;27:1015\u201321.","journal-title":"Clin Microbiol Infect"},{"key":"2168_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","volume":"24","author":"S Lee","year":"2018","unstructured":"Lee S, Song KH, Jung SI, Park WB, Lee SH, Kim YS, et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Clin Microbiol Infect. 2018;24:152\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"2168_CR14","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/jac\/dky259","volume":"73","author":"MR Bidell","year":"2018","unstructured":"Bidell MR, Patel N, O\u2019Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 2018;73:2643\u201351.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02168-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02168-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02168-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T17:07:12Z","timestamp":1717175232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02168-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2168"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02168-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. The authors declare they have no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the Ethics Commission of the Faculty of Medicine of Cologne University (18 June 2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}